

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 August 2023 (31.08.2023)



(10) International Publication Number
WO 2023/164688 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 14/74 (2006.01)
C07K 14/725 (2006.01) C07K 14/705 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/063333

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

27 February 2023 (27.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/314,848 28 February 2022 (28.02.2022) US

(71) Applicant: **KITE PHARMA, INC.** [US/US]; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: **FENG, Jun**; 12907 Seabreeze Farms Drive, San Diego, California 92130 (US). **KRISHNAMURTY, Chloe Knights**; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **SCHLUNS, Kimberly Sue**; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(74) Agent: **GRIMM, Nicole E.** et al.; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ALLOGENEIC THERAPEUTIC CELLS

(57) Abstract: The present disclosure provides allogeneic cells that cause reduced, minimal, or no risks of graft-versus-host disease (GVHD) and reduced, minimal, or no risk of CD4, CD8 and NK cell rejections, for example, when used to treat diseases in a patient. The allogeneic cells may be genetically engineered to reduce the expression or activity of MHC class I and/or MHC class II molecules, such as knocking out the RFX5 gene. Methods of preparing and using such allogeneic cells are also provided.

WO 2023/164688 A1